FDA in Turmoil: Health Leaders Demand Stability and Independent Science From the Next Commissioner

The U.S. Food and Drug Administration faces a moment of deep uncertainty. Commissioner Marty Makary, MD, MPH, stepped down in protest recently after a high-profile disagreement with President Trump. At the center of the split: the agency’s decision to allow flavored e-cigarettes onto the market. Now, health leaders, patient advocates, and drug industry representatives are speaking out about what they want to see in the next FDA chief. Their message is clear: bring back regular order, shield science from politics, and rebuild public trust.

Why the FDA Commissioner Matters to Your Health

Most people do not think about the FDA every day, but the agency’s decisions touch nearly every part of your health and wellness. The FDA oversees the safety of medicines, vaccines, medical devices, food, cosmetics, and tobacco products. When you take a prescription drug, eat a salad, or use a vape pen, the FDA is supposed to make sure those products are safe and effective. The Commissioner sets the tone for the entire agency. That person decides what gets priority, how quickly new treatments are reviewed, and how much influence outside politics or industry pressure has over the scientific process.

When the FDA operates smoothly and follows consistent, science-based rules, patients and doctors can trust that approved treatments are safe. Drug companies and device makers can plan long-term research and investment because they know what standards they must meet. Public health officials can rely on the agency to make tough calls without political interference. But when the agency’s leadership is in chaos, all of that can falter.

The Controversy That Led to Makary’s Resignation

The immediate cause of the shake-up was a battle over e-cigarettes. For years, public health groups have worried about flavored vapes attracting teenagers and young adults. Fruit, candy, and dessert-like flavors can make vaping seem harmless, but nicotine is highly addictive. The FDA under previous administrations took a cautious approach to flavored e-cigarettes, keeping many off the market unless manufacturers could prove they helped adult smokers quit without drawing in kids.

Under President Trump’s second term, pressure mounted to authorize more flavored vape products. Early this month, after direct urging from the president, the FDA approved fruit-flavored vapes for marketing. Commissioner Makary disagreed strongly with that decision and chose to resign rather than carry it out. His departure highlights just how much personal influence the White House can exert on what is supposed to be an independent regulatory body.

What Experts Say the FDA Needs Most Now

At a recent Future of Health Summit, leading voices from the pharmaceutical industry, consumer advocacy groups, and public health organizations laid out their expectations for the next commissioner. Their insights offer a roadmap for restoring credibility and function to an agency under enormous strain.

Stability and Predictability for Medical Innovation

Stephen J. Ubl, president and CEO of Pharmaceutical Research and Manufacturers of America (PhRMA), stressed that drug developers are looking for a calm, steady hand. “I think what we really need from the next leader of the FDA is to calm the waters and re-establish that certainty and predictability,” he said. When companies do not know what rules will apply from one month to the next, Ubl warned, investment in new treatments can freeze. The science behind developing a new drug takes years and costs billions of dollars. Without a clear regulatory path, that life-saving research might never get started.

For patients waiting on better cancer therapies, Alzheimer’s treatments, or rare disease cures, a stable FDA is not just a bureaucratic nicety—it directly affects the pipeline of new medicines. The next commissioner must send a signal that the FDA will stick to transparent, consistent standards so that innovation can flourish.

Rebuilding the Workforce and Restoring Process

Peter Lurie, MD, MPH, president and executive director of the Center for Science in the Public Interest, pointed to two urgent areas: operations and policy. On the operations side, he noted, “they’ve got several thousand people who they need to rehire.” The mass layoffs and encouraged resignations that swept through the Department of Health and Human Services (HHS) in recent months have hollowed out key offices. The FDA lost seasoned scientists, reviewers, and inspectors. Getting those experts back—or hiring and training new ones—will be essential to keeping food and drug safety on track.

Lurie also wants to see the return of conventional decision-making processes. In the past, the FDA regularly held open advisory committee meetings where outside experts and the public could weigh in on tough calls. Comment periods allowed patients, doctors, and companies to share data and perspectives. Under Makary, Lurie said, these meetings dwindled. He described a pattern of agency leaders sidelining career staff by using handpicked “expert panels” that operate behind closed doors and bypass public input. At times, he added, officials seemed to “rule from the pages of the New England Journal of Medicine,” making announcements through medical journal articles rather than through the usual transparent regulatory channels.

“What we have now are inconsistent scientific standards, where certain products are subject to what seem to be very high standards because they’re disfavored, and others are subject to reduced standards because they’re favored,” Lurie said. He offered vaccines as an example of products facing extremely strict scrutiny, while vapes have enjoyed a more lenient approach. The next commissioner, experts argue, must apply the same rigorous, evidence-based yardstick to every product, regardless of political winds.

Science Over Politics: Insulating the Agency

Robert Steinbrook, MD, health research group director for Public Citizen, an advocacy group focused on healthcare, echoed many of Lurie’s concerns. He emphasized that the next leader must protect the FDA’s career scientists and medical officers. “The next FDA commissioner should insulate career FDA staff from political pressure and industry pressure,” Steinbrook said. That means creating a firewall so that White House preferences or powerful lobbying do not override scientific judgment. “The commissioner should recommit the agency to following standard regulatory processes and focusing on public health, not the wish lists of the White House or … Kennedy.”

That mention of Kennedy refers to Robert F. Kennedy Jr., the current Secretary of Health and Human Services. The HHS secretary oversees the FDA and can influence its direction. Kennedy has publicly questioned vaccine safety and other established public health measures on multiple occasions. Having a layer of political leadership that holds views at odds with mainstream medical science makes the FDA’s independence even more critical. Steinbrook stressed that the agency must be allowed to do its job without “drama and chaos.”

“For the FDA to move forward, the drama and chaos that characterized the Makary era must end,” Steinbrook said. “The agency should be allowed to do its many jobs, including moving forward with sensible reforms to improve the agency’s efficiency and effectiveness.”

The Bigger Problems at Health and Human Services

Lurie cautioned that the FDA’s troubles cannot be viewed in isolation. “It’s fine to say that FDA is in disarray … but you have to look higher up at HHS in general, and they’re having a very hard time filling the most basic positions in the administration,” he said. As an example, Lurie pointed out that Jay Bhattacharya, MD, PhD, is currently running both the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC)—two sprawling agencies that would normally have separate, full-time directors. Meanwhile, President Trump recently announced his third nominee for the position of U.S. Surgeon General, a role that remains unfilled.

This leadership vacuum means critical health decisions are being made by an ever-thinner bench of political appointees, many without deep experience in the sprawling regulatory work that protects Americans every day. The next FDA commissioner will step into an environment where the parent department itself is stretched thin, which makes steady, non-political leadership at the FDA even more essential.

Lurie added that any candidate willing to take the FDA job under these conditions must be “very brave,” because the individual will be subject not only to the whims of Secretary Kennedy but also the president. It is a role that demands both scientific expertise and the courage to say no when evidence demands it.

What This Means for You

The direction the FDA takes under a new commissioner will shape the health landscape for years. Here are a few practical ways these leadership decisions could touch everyday life:

• Medication Safety and Availability: If the FDA rushes approvals or cuts corners to satisfy political goals, unsafe or ineffective drugs could reach the market. On the other hand, a return to predictable processes could speed up access to genuinely innovative treatments by making the rules clear.
• Youth Vaping: The controversy over flavored e-cigarettes directly affects families. Lax standards could mean more sweet-flavored vapes end up in the hands of teenagers, potentially hooking a new generation on nicotine. Stricter, science-based regulation could help reverse that trend.
• Vaccine Confidence: When the FDA is seen as a political tool rather than a science-driven guardian, public trust in vaccines erodes. A commissioner who stands up for career scientists and transparent reviews can help rebuild that trust, which is vital for community immunity against diseases like measles and flu.
• Food and Cosmetic Safety: The agency inspects food facilities and monitors cosmetic ingredients. With thousands of staff gone, inspection backlogs could grow, meaning contaminated food or harmful chemicals in makeup might slip through the cracks. The next leader must prioritize rebuilding that safety net.
• Your Voice in Decisions: Open advisory committee meetings and public comment periods allow ordinary citizens, patient groups, and independent experts to have a say on new products. Rest
  Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any health decisions. Content reviewed by the HealthyMag Editorial Team.

  Source: MedPage Today